Abstract
We investigated feasibility of positron emission tomography (PET) with [11C]SA4503 for evaluating the sigmai receptor occupancy rate by neuroleptics. Haloperidol, which is well known to bind dopamine D2-like receptor (D2R) as well as to be a representative non-selective antagonist for sigmai receptor (σ1R), was selected as a model drug. Three healthy male subjects underwent 60-min [11C]raclopride-PET and 90-min [11C]SA4503-PET scans successively at a 120-min interval twice in a day for baseline measurement and on another day for haloperidol-loading measurement 16 hours after peroral administration of 3 mg of haloperidol. Binding potential (BP) of [11C]raclopride and [11C]SA4503 was quantitatively evaluated and the σ1R and D2R occupancy rates were determined. D2R occupancy rates by haloperidol were 64% and 62% in the caudate and putamen, respectively, 16 h after the administration, while σ1R occupancy rates were approximately 80% in all seven regions investigated including the caudate, putamen and cerebellum 18 h after the administration, suggesting that the σlR receptor occupancy rate by haloperidol was slightly larger than the D2R receptor occupancy rate. We concluded that [11C]SA4503-PET can be used for evaluating the σlR occupancy rates by neuroleptics or other drugs.
This is a preview of subscription content, log in via an institution to check access.
References
Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl 4): 83–89.
Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L. Implications of brain imaging for the management of schizophrenia.Int Clin Psychopharmacol 1998; 13 (Suppl 3): S15–20.
Tashiro M, Mochizuki H, Sakurada Y, Ishii K, Oda K, Kimura Y, et al. Brain histamine H1 receptor occupancy of orally administered antihistamines measured by positron emission tomography with11C-doxepin in a placebo- controlled crossover study design in healthy volunteers: a comparison of olopatadine and ketotifen.Br J Clin Pharmacol 2006; 61: 16–26.
Debonnel G, de Montigny C. Modulation of NMD A and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders.Life Sci 1996; 58: 721–734.
Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC. Sigma receptors: biology and function.Pharmacol Rev 1990; 42: 355–402.
Hashimoto K, Ishiwata K. Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals.Curr Pharm Design 2006; 12: 3915–3928.
Kawamura K, Ishiwata K, Tajima H, Ishii S, Matsuno K, Homma Y, et al.In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors.Nucl Med Biol 2000; 27: 255–261.
Kawamura K, Ishiwata K, Shimada Y, Kimura Y, Kobayashi T, Matsuno K, et al. Preclinical evaluation of [11C]SA4503: radiation dosimetry,in vivo selectivity and PET imaging of sigmai receptors in the cat brain.Ann Nucl Med 2000; 14: 285–292.
Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, et al. An increase of sigmai receptors in the aged monkey brain.Neurobiol Aging 2003; 24: 745–752.
Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, et al. Function of sigmai receptors in Parkinson’s disease.Acta Neurologica 2005; 112: 103–107.
Ishiwata K, Kawamura K, Kobayashi T, Matsuno K. Sigmai and dopamine D2 receptors occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands.Nucl Med Biol 2003: 30: 429–434.
Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial field- of-view PET scanner: SET-2400W.Ann Nucl Med 1997; 11:307–313.
Langer O, Någren K, Dolle F, Lundkvist C, Sandeil J, Swahn CG, et al. Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate.J Label Compds Radiopharm 1999; 42: 1183–1193.
Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF. Exact and approximate rebinning algorithms for 3-D PET data.IEEE Trans Med Imaging 1997; 16: 145–158.
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.Neurolmage 1997; 6: 279–287.
Frieboes RM, Murck H, Antonijevic I, Kraus T, Hinze-Selch D, Pollmacher T, et al. Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls.Psychopharmacology (Berl) 1999; 141: 107–110.
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N- 11C-methyl]-(-)-cocaine PET studies in human subjects.J Cereb Blood Flow Meta 1990; 10: 740–747.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishiwata, K., Oda, K., Sakata, M. et al. A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med 20, 569–573 (2006). https://doi.org/10.1007/BF03026824
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03026824